PALI's share count increased dramatically from 4.4 million to 165.9 million shares outstanding, indicating massive dilution likely from equity raises to fund operations amid worsening losses.
The roughly 38x increase in shares outstanding represents extreme dilution that significantly impacts existing shareholders' ownership percentage. This massive equity issuance was likely necessary to fund continuing operations as the clinical-stage company burns cash, but comes at a steep cost to current investors who now own a much smaller slice of the company.
The company's financial position deteriorated with operating losses widening to $18.1M from $14.9M and net losses expanding to $16.8M. However, debt decreased substantially from $1.1M to $87K, and operating cash flow modestly improved to -$10.8M from -$12.2M, suggesting some operational efficiency gains. The overall picture shows a cash-burning clinical company that required significant equity dilution to maintain funding, though debt reduction and slightly improved cash burn provide some positive signals.
Debt reduced 92.4% — deleveraging strengthens balance sheet and reduces financial risk.
Liabilities grew 46.5% — significant increase in debt or obligations, assess impact on financial flexibility.
Current liabilities surged 43.3% — significant near-term obligations; verify ability to meet short-term debt.
Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Net income declined 16.2% — review whether driven by operations, interest costs, or non-recurring items.
Operating cash flow grew 11% — strong conversion of earnings to cash, healthy business fundamentals.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →